Plain-English translation of NCT06316960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called combined with standard chemotherapy to treat children whose acute myeloid leukemia (a serious blood cancer) has returned after treatment or didn't respond to the first round of therapy. The medication targets a specific genetic change (a KIT mutation) that may make the cancer more likely to come back. Researchers want to see if this medication helps more children beat this particular type of leukemia.
About 30% of children with this type of leukemia still relapse even with current best treatments. Recent studies suggest that the medication has promise for controlling this cancer, and this trial will formally test whether it is safe and effective enough to help more children.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as part of a combination treatment that includes standard chemotherapy drugs. The medication starts at a lower dose and may be increased after about one week if your blood counts are stable. Treatment cycles last up to 28 days, and the medication may be temporarily stopped if you develop an infection, then resumed once the infection clears. You'll be monitored closely with blood tests and medical visits throughout the trial, which takes place across 11 hospitals in China.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China